SUPEUDOL 10 10 MG
OXYCODONE HYDROCHLORIDE : 10 MG · DIN 00443948 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SUPEUDOL 10?
SUPEUDOL 10 10 MG contains OXYCODONE HYDROCHLORIDE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00443948, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 05-Aug-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SUPEUDOL 10 used for?
Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. Supeudol® 5 / Supeudol® 10 is not indicated as an as-needed (prn) analgesic.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00443948 |
|---|---|
| Brand name | SUPEUDOL 10 |
| Generic / active ingredient | OXYCODONE HYDROCHLORIDE : 10 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA05 OXYCODONE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 05-Aug-2005 |
| Original market date | 1980-12-31 00:00:00 |
How is it administered?
Individualized dosing. Opioid-naive: 5-10 mg every 6 hours. Swallow whole; do not crush or chew. Titrate to lowest effective dose. Maximum 7 days for acute pain.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
null
How is it supplied?
Supeudol® 5: 5 mg tablets are available in polyethylene bottles of 100 tablets. Supeudol® 10: 10 mg tablets are available in polyethylene bottles of 100 tablets.
Contraindications
Hypersensitivity to oxycodone; GI obstruction (e.g., ileus); acute abdominal pain; severe asthma or COPD; respiratory depression; acute alcoholism; convulsive disorders; head injury; use of MAOIs.
Warnings and precautions
Risk of addiction, abuse, and misuse. Fatal respiratory depression may occur. Concomitant use with alcohol or benzodiazepines may lead to coma or death. Accidental ingestion can be fatal.
What can be used instead?
Other Canadian products sharing ATC code N02AA05 OXYCODONE. 28 of 68 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-OXYCODONE CR | 10 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02366754 |
| APO-OXYCODONE CR | 15 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02394766 |
| APO-OXYCODONE CR | 20.0 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02366762 |
| APO-OXYCODONE CR | 30 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02394774 |
| APO-OXYCODONE CR | 40 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02306530 |
| APO-OXYCODONE CR | 5.0 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02366746 |
| APO-OXYCODONE CR | 60 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02394782 |
| APO-OXYCODONE CR | 80.0 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02366789 |
| OXY.IR | 10 MG | TABLET | PURDUE PHARMA | MARKETED | DIN 02240131 |
| OXY.IR | 20 MG | TABLET (IMMEDIATE RELEASE) | PURDUE PHARMA | MARKETED | DIN 02240132 |
Who else supplies OXYCODONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. OXYCODONE appears in 240 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.